LAKE FOREST, Illinois – January 31, 2024 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).

LAKE FOREST, Ill., May 16, 2022 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced results of two preclinical studies of JAG101 in two different animal models of Type 1 galactosemia. Results showed that low and high doses of intravenous JAG101 given as a one-time gene replacement therapy reduced levels of toxic metabolites in brain and liver tissues and increased GALT enzyme expression and activity in tissues relevant to long-term outcomes in Type 1 galactosemia.

LAKE FOREST, Ill., March 29, 2022 –(BUSINESS WIRE)–Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases including those that impact sizeable patient populations, today announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes (T1D), have invested in the company.

LAKE FOREST, Ill., Oct. 26, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for larger patient populations suffering from severe genetic diseases, today announced plans for a commercial manufacturing facility in Durham, North Carolina.